Gentian Diagnostics ASA (OSL: GENT)

Market Cap	623.06M
Revenue (ttm)	154.12M
Net Income (ttm)	2.22M
Shares Out	15.42M
EPS (ttm)	0.14
PE Ratio	280.65
Forward PE	40.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,624
Average Volume	1,905
Open	40.20
Previous Close	40.20
Day's Range	40.20 - 41.00
52-Week Range	34.80 - 61.00
Beta	0.52
RSI	51.19
Earnings Date	Feb 12, 2025

About Gentian Diagnostics ASA

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentia...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 58
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2023, Gentian Diagnostics ASA's revenue was 142.35 million, an increase of 27.18% compared to the previous year's 111.92 million. Losses were -10.65 million, -54.92% less than in 2022.